Pediatric dilated cardiomyopathy is a myocardial disease of childhood characterized by ventricular dilation and systolic dysfunction, often leading to heart failure and transplant risk.
Longeveron Inc. announced Phase 2b clinical trial results published in Cell Stem Cell showing laromestrocel improved physical condition in patients with age-related frailty after nine months compared to placebo.
Longeveron Inc. appointed Stephen H. Willard as CEO effective February 11, 2026, replacing interim CEO Than Powell. The appointment comes as the company expects top-line results from its pivotal Phase 2b trial for Hypoplastic Left Heart Syndrome in Q3 2026.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07197372 |
Comparative Efficacy of ARNI Versus ACE Inhibitor Therapy in Egyptian Children With Dilated Cardiomyopathy |
NOT_YET_RECRUITING | |
| NCT03214757 |
A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy |
UNKNOWN | |
| NCT02847585 |
Potential Role of Water-soluble Ubiquinol in Complementary Therapy for Pediatric Dilated Cardiomyopathy |
COMPLETED | NA |
